Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Allo-HCT outcomes for AML patients with NUP98 rearrangements: A study on behalf of the global committee, the ALWP and the PDWP of the EBMT

Lin Li, Yishan Ye, Jacques-Emmanuel Galimard et al. Nov 03, 2025 pp. 4270-4270 10.1182/blood-2025-4270

Abstract Background Acute myeloid leukemia (AML) with NUP98 rearrangements on chromosome 11p15 is a high-risk subtype with poor prognosis. D...

Socio-clinical determinants and demographic disparities of survival in splenic marginal zone lymphoma: A retrospective cohort study

Manas Pustake, Oboseh Ogedegbe, Yashodhan Morye et al. Nov 03, 2025 pp. 3579-3579 10.1182/blood-2025-3579

Abstract Background: Splenic marginal zone lymphoma (SMZL) is an uncommon, typically indolent type of B-cell lymphoma originating in the sple...

Hepatic intravital imaging reveals the contribution of peptidylarginine deiminase 4 (PAD4) to the spatiotemporal dynamics of neutrophil recruitment and NET release during bacterial infection

Weronika Ortmann, Anna Prykhodko, Hyunjun Kim et al. Nov 03, 2025 pp. 1221-1221 10.1182/blood-2025-1221

Abstract Background: Intravital imaging is a powerful tool for investigating dynamic biologic processes such as neutrophil (PMN) recruitment...

Survival difference among patients with large B-cell lymphoma (LBCL)  based on first-line clinical trial participation: A multi-institutional analysis of 8 academic institutions in the lymphoma epidemiology of outcomes (LEO) cohort

Chijioke Nze, Clark Andersen, Matthew Maurer et al. Nov 03, 2025 pp. 895-895 10.1182/blood-2025-895

Abstract Background: Despite advances in LBCL treatment, 35–45% of patients relapse or have refractory disease highlighting an unmet clinica...

CD19/CD22 CAR-T cells in adult patients with relapsed/refractory B-cell malignancies

Laurent Phely, Stefan Hug, Luca Hensen et al. Nov 03, 2025 pp. 4142-4142 10.1182/blood-2025-4142

Abstract Background: Dual-targeted CAR-T cell therapies may help overcome mechanisms of resistance associated with antigen escape. We evalua...

Autologous and allogeneic stem cell transplantation for ALK-positive anaplastic large cell lymphoma: An analysis of the EBMT lymphoma working party

Evgenii Shumilov, Maud Ngoya, Philipp Berning et al. Nov 03, 2025 pp. 891-891 10.1182/blood-2025-891

Abstract Background Adults with anaplastic lymphoma kinase-positive anaplastic large cell lymphoma (ALK-pos. ALCL) treated with CHOP or vari...

Artificial intelligence‑driven virtual tumor board enhances precision care in myelodysplastic syndromes (MDS)

David Swoboda, Amy DeZern, James England et al. Nov 03, 2025 pp. 7363-7363 10.1182/blood-2025-7363

Abstract Background and Aims Myelodysplastic syndromes (MDS) present significant diagnostic and therapeutic challenges, often requiring inpu...

Commpass explorer: An interactive platform to explore clinico-genomic data from newly diagnosed multiple myeloma patients from the commpass observational trial

Wanxing Zhang, Chaitanya Acharya, Steven Foltz et al. Nov 03, 2025 pp. 7470-7470 10.1182/blood-2025-7470

Abstract The CoMMpass study (NCT01454297) is a prospective, longitudinal observational trial involving 1,141 newly diagnosed, treatment-naïv...

Diverse preferences for treatment options in relapsed/refractory (R/R) follicular lymphoma (FL): Survey results from patients in the United States (US)

Krish Patel, Esprit Ma, Mei Wu et al. Nov 03, 2025 pp. 6180-6180 10.1182/blood-2025-6180

Abstract Background: Since 2020, several novel treatments (Txs) that differ in duration, dosing frequency, route of administration, efficacy...

FLIPI24 as a prognostic model in marginal zone lymphoma: Results from an international multi-cohort analysis

Prokop Vodička, Matthew Maurer, Michal Masar et al. Nov 03, 2025 pp. 1826-1826 10.1182/blood-2025-1826

Abstract Introduction Marginal zone lymphoma (MZL) is an indolent and heterogenous disease. Several prognostic models have been proposed to...

CD123-directed chimeric antigen receptor T-cell (CART123) therapy for relapsed/refractory pediatric acute myeloid leukemia

Lucy Cain, Yimei Li, Anand Bhagwat et al. Nov 03, 2025 pp. 1643-1643 10.1182/blood-2025-1643

Abstract Introduction Clinical outcomes of children, adolescents and young adults (CAYA) with second or greater relapsed or refractory (r/r)...

Reassessing bone marrow staging practices in limited-stage follicular lymphoma in the PET era

Marissa Solow, Carolyn Owen, Colin Stewart et al. Nov 03, 2025 pp. 2772-2772 10.1182/blood-2025-2772

Abstract Introduction: Bone marrow (BM) involvement is present in approximately 50% of patients with follicular lymphoma (FL) and is associa...

Comparison of alemtuzumab and ATG-based conditioning in adult recipients of allogeneic hematopoietic cell transplantation (HCT) for severe aplastic anemia: A retrospective study

Murad Almowarey, Nihar Desai, Mohammed Kawari et al. Nov 03, 2025 pp. 4207-4207 10.1182/blood-2025-4207

Abstract Background The optimal in-vivo T-cell depleting agent for allogeneic hematopoietic cell transplantation (HCT) for patients with sev...

Early efficacy and safety of luspatercept in myelofibrosis-associated anemia: A clinical study with biomarker exploration

Junyao Huang, Ting Niu, Ling Pan et al. Nov 03, 2025 pp. 1116-1116 10.1182/blood-2025-1116

Abstract Background: Anemia is a prevalent and prognostically adverse complication in myelofibrosis (MF). Although preliminary studies sugge...

Identification of small molecules that selectively target JAK2V617F driven cytokine-independent megakaryopoiesis by leveraging single cell RNA sequencing maps of myelofibrosis patients samples and a deep learning framework

Mauricio Cortes, Stephan Sachs, Jennifer O'Brien et al. Nov 03, 2025 pp. 389-389 10.1182/blood-2025-389

Abstract In myeloproliferative neoplasms including myelofibrosis (MF), the accumulation of driver mutations like JAK2V617F in the hematopoie...

Tradeoff between vaccine-induced immunity and depth of response following autologous stem cell transplantation in multiple myeloma

David Foureau, Dragos Plesca, Fei Guo et al. Nov 03, 2025 pp. 4005-4005 10.1182/blood-2025-4005

Abstract Introduction: Immunizations are routinely administered to confer protection against vaccine-preventable infections during both early...

Real-life CD34+CD38- leukemic stem cell (LSC) flow quantification in adult AML at diagnosis independently predicts survival of intensively but not AZA-VEN treated patients: A study of prospective observational ALFA-PPP acute leukemia french association

Adriana Plesa, Alexandra COELHO, Stéphanie Mathis et al. Nov 03, 2025 pp. 3483-3483 10.1182/blood-2025-3483

Abstract Introduction CD34+CD38- leukemic stem cell (LSC) is a key prognostic marker in AML at diagnosis and follow-up in intensive clinical...

Impact of pain sensitization phenotypes on quality of life among adults with sickle cell disease

Rachael Ajiboye, Yingwei Yao, Yenisel Cruz-Almeida et al. Nov 03, 2025 pp. 4720-4720 10.1182/blood-2025-4720

Abstract Introduction: Recent research has shown that sensitization contributes to chronic pain phenotypes in adults with sickle cell diseas...

The phase II study of zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma (DLBCL) patients with specific gene-expression

Qunling Zhang, Shiyu Jiang, Yizhen Liu et al. Nov 03, 2025 pp. 57-57 10.1182/blood-2025-57

Abstract Background: Diffuse Large B cell Lymphoma (DLBCL) is the most common type of non-Hodgkin Lymphoma (NHL), with R-CHOP chemotherapy (...

Interrelationship between endothelial dysfunction and inflammation and outcomes in pulmonary embolism

Martin Lundy, Mira Nigudkar, Fakiha Siddiqui et al. Nov 03, 2025 pp. 4872-4872 10.1182/blood-2025-4872

Abstract Introduction: Acute pulmonary embolism (PE) is the third leading cause of death with a mortality rate upwards of 30% if left untrea...

DNA-based MRD monitoring enhances risk stratification during TKI dose reduction in CML: Evidence from the clinical trial

Katerina Machova Polakova, Hana Žižková, Romana Vajnerova et al. Nov 03, 2025 pp. 78-78 10.1182/blood-2025-78

Abstract Background: In chronic myeloid leukemia (CML), DNA-based measurable residual disease (MRD) analysis—either combined with RNA MRD (M...

Laboratory characteristics of monoclonal gammopathy of undetermined significance (MGUS) in a diverse sample from three large cancer epidemiology cohorts.

Jane Emerson, Sabrina Racine Brzostek, Yachana Kataria et al. Nov 03, 2025 pp. 5749-5749 10.1182/blood-2025-5749

Abstract Introduction: Monoclonal gammopathy of undetermined significance (MGUS) is a precursor of multiple myeloma (MM) and shares many ris...

Perioperative anemia and transfusion thresholds in vascular surgery procedures – a systematic review

Alexander Xiang, Allen Li, Ali Eshaghpour et al. Nov 03, 2025 pp. 4921-4921 10.1182/blood-2025-4921

Abstract Background Anemia is a common condition, with an estimated 1.92 billion cases, or 24.3% of the worldwide population as of 2021, and...

Incidence of CMV-reactivation in multiple myeloma patients receiving bispecific antibodies

Jordan Snyder, Dennis Grauer, James Davis et al. Nov 03, 2025 pp. 5802-5802 10.1182/blood-2025-5802

Abstract Introduction: Cytomegalovirus (CMV) reactivation is common following allogenic hematopoietic stem cell transplant and CAR T-cell th...

Real-world efficacy of inaticabtagene autoleucel in adult B-cell acute lymphoblastic leukemia patients with high-risk molecular alterations

Xuan Zhou, Jin Wang, Hongsheng Zhou et al. Nov 03, 2025 pp. 6865-6865 10.1182/blood-2025-6865

Abstract Background Adult patients with B-cell acute lymphoblastic leukemia (B-ALL) harboring high-risk molecular alterations face an unfavo...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page